Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant plasma cell lines express a functional CD28 molecule

X G Zhang1, D Olive, J Devos

  • 1Institute of Molecular Genetics, Unit for Cellular Therapy, Hôpital Saint Eloi, Montpellier, France.

Leukemia
|April 29, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Numerical simulation of vertical cavity surface emitting lasers.

Optics express·2009
Same author

[Colonic perforation after extracorporeal shock wave lithotripsy].

Deutsche medizinische Wochenschrift (1946)·2009
Same author

Thyroid surgery in Burkina Faso, West Africa: experience from a surgical help program.

World journal of surgery·2008
Same author

[Oocyte and embryo quality: do the apoptotic markers have a place in the preimplantation genetic diagnostic?].

Gynecologie, obstetrique & fertilite·2008
Same author

[Could apoptotic markers help the exploration of male infertility?].

Gynecologie, obstetrique & fertilite·2008
Same author

ETV6 mutations and loss in AML-M0.

Leukemia·2008
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026
Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026
See all related articles

CD28 molecules on myeloma cells bind B7, but do not activate proliferation. This interaction may impair immune control of human myeloma cell lines (HMCL).

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • CD28 is a key T-cell costimulatory receptor.
  • Its role on malignant plasma cells in human myeloma cell lines (HMCL) is not fully understood.
  • Myeloma cells express CD28 and interact with B7 ligands.

Purpose of the Study:

  • To investigate the function and signaling capacity of CD28 on malignant plasma cells.
  • To determine if CD28-B7 interactions influence HMCL proliferation, survival, or differentiation.
  • To explore the potential of CD28-mediated signaling in immune evasion by myeloma cells.

Main Methods:

  • Flow cytometry to assess CD28 and B7 antigen expression on HMCL.
  • Binding assays using B7-Ig, B7-1 transfectants, and CTLA-4 protein.

Related Experiment Videos

  • Inhibition studies with anti-CD28 monoclonal antibody (mAb).
  • Assessment of PI-3 kinase p85 subunit binding to CD28.
  • Evaluation of IL-6-dependent and autonomous proliferation assays.
  • Analysis of cell proliferation, survival, differentiation, and cytokine production post-stimulation.

    • Main Results:

    • HMCL express CD28 at densities similar to normal T cells and can bind B7-Ig and B7-1 transfectants.
    • Myeloma cells express low levels of B7-2 but not B7-1, and these B7-2 molecules bind CTLA-4.
    • No evidence of autocrine CD28:B7-2 activation or impact on IL-6-dependent/autonomous proliferation was observed.
    • Activation of myeloma CD28 did not affect proliferation, survival, differentiation, or cytokine production.
    • Triggering CD28 by B7-1 transfectants induced PI-3 kinase p85 subunit binding, similar to T cells.

    Conclusions:

    • Myeloma cells express functional CD28 molecules capable of binding B7 ligands.
    • Despite binding capacity, CD28 engagement does not directly drive HMCL proliferation or survival.
    • The expression of CD28 on myeloma cells, potentially interacting with B7 molecules, may contribute to immune evasion and downregulation of anti-myeloma immune responses.